Adaptimmune Therapeutics plc (ADAP)

1,1900 0,0000 (0,00%) Alla chiusura: 04:00PM EDT

Adaptimmune Therapeutics plc

60 Jubilee Avenue
Milton Park
Abingdon OX14 4RX
United Kingdom
44 12 3543 0000
https://www.adaptimmune.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 449

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Adrian G. Rawcliffe	CEO, Principal Accounting Officer & Director	1,06M	199,16k	1972
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.	Co-Founder & Chief Business & Strategy Officer	677,4k	N/D	1967
Mr. Gavin Hilary James Wood ACA, BA (Hons)	Chief Financial Officer	666,34k	N/D	1970
Mr. William C. Bertrand Jr., Esq., J.D.	Chief Operating Officer	707,34k	76,95k	1965
Dr. Elliot Norry B.A., M.D.	Chief Medical Officer	676,19k	65,02k	1964
Ms. Joanna Brewer Ph.D.	Chief Scientific Officer	N/D	N/D	1976
Dr. Juli P. Miller Ph.D.	VP of Corporate Affairs & Investor Relations	N/D	N/D	N/D
Ms. Kerry Sharp	Senior VP & General Council	N/D	N/D	N/D
Dana Lynch	Senior Director of Corporate Communications	N/D	N/D	N/D
Mr. John Lunger	Chief Patient Supply Officer	645,91k	148,2k	1970

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Adaptimmune Therapeutics plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.